Type I interferon response in the nose during respiratory viral infections in older adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study analyzes the nasal Type I interferon response in geriatric patients with respiratory viral infections. It compares the IFN-I score to first-line PCR tests for SARS-CoV-2, RSV, and influenza, using samples collected as part of routine care. The goal is to see if host-response markers can aid diagnosis when not all respiratory viruses are tested for individually. No intervention is applied beyond measuring the interferon response, and the study leverages existing clinical data from the REFIPA cohort. Findings could inform future diagnostic approaches in elderly populations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients admitted to a geriatric ward or participants diagnosed with a PCR-positive infection based on a swab sample taken as part of the REFIPA study (NCT07239830). Nasopharyngeal swab taken for viral detection, where the viral test was carried out as part of standard clinical care (minimum 500 µL required)

Exclusion Criteria:

* The patient's objection to the use of their data in this study

Where it's running

• Hôpital Lyon Sud
  Lyon, France Recruiting

Study contacts

• Study coordinator: Sophie S TROUILLET-ASSANT, PHD
• Email: sophie.trouillet-assant@chu-lyon.fr
• Phone: 04 72 67 87 80

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AP1189 added to standard care for adults hospitalized with respiratory viral infections

  This study tests whether taking AP1189 once daily for 14 days, in addition to standard care, helps hospitalized patients with pneumonia-like breathing problems caused by a respiratory virus.

  Recruiting at 10 sites Phase 2 SynAct Pharma Aps · Mostar, Herzegovina-Neretva Canton and 10 other locations · NCT07633288

• JKN2301 dry suspension versus oseltamivir for treating flu in children 2 to under 12.

  This study tests whether JKN2301 dry suspension is safe and helps treat uncomplicated influenza in children aged 2 to 11, compared with oseltamivir or placebo.

  Recruiting Phase 3 Joincare Pharmaceutical Group Industry Co., Ltd · Guangzhou, Guangdong · NCT07357051

• A program to empower community health workers to combat vaccine misinformation

  This study is testing a program that helps community health workers from Hispanic backgrounds use their personal stories to fight vaccine misinformation and boost vaccination rates in their communities.

  Recruiting University of Chicago · Chicago, Illinois and 3 other locations · NCT06417762

• Understanding how respiratory infections affect lung inflammation from ozone exposure

  This study is testing how past respiratory infections affect lung inflammation in people aged 18-55 when they are exposed to ozone.

  Recruiting Phase 1 Duke University · Durham, North Carolina · NCT05773001

• Understanding respiratory viral infections in pediatric transplant recipients

  This study is trying to see if measuring respiratory viruses before a transplant can help predict which kids might get respiratory infections afterward.

  Recruiting at 27 sites Arkansas Children's Hospital Research Institute · Birmingham, Alabama and 26 other locations · NCT05550298

• Breath test to tell if a child has a viral respiratory infection vs. a healthy kid

  This pilot test checks whether the MBP Breath Analyzer can detect distinct breath signatures in kids with acute respiratory infection compared to healthy peers.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07902115

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.